These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24105799)

  • 1. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
    de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
    J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
    Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
    te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
    J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.
    Hoeben E; Neyens M; Mannaert E; Schmidt M; Vermeulen A
    Clin Pharmacokinet; 2013 Nov; 52(11):1005-15. PubMed ID: 23754735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
    Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
    Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats.
    Krishna G; Gopalakrishnan G; Goel S
    Toxicol Mech Methods; 2017 Jun; 27(5):352-362. PubMed ID: 28142338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2008 Jan; (545):1-240. PubMed ID: 18685716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
    Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
    J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
    Zhang J; Ye L; Wang W; Du G; Yu X; Zhu X; Dong Q; Cen X; Guan X; Fu F; Tian J
    Hum Exp Toxicol; 2015 Feb; 34(2):205-23. PubMed ID: 24812153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection.
    Schmidt ME; de Boer P; Andrews R; Neyens M; Rossenu S; William Falteos D; Mannaert E
    Psychopharmacology (Berl); 2012 Dec; 224(4):549-57. PubMed ID: 22773165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigenerational reproductive study of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2008 Mar; (539):1-266. PubMed ID: 18685713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
    Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
    Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP toxicity report of reproductive dose range-finding study of Genistein (CAS No. 446-72-0) administered in feed to Sprague-Dawley rats.
    Delclos KB; Newbold R
    Toxic Rep Ser; 2007 Nov; (79):1-C2. PubMed ID: 18685712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.